Proposed Information Collection Activity: Title V State Sexual Risk Avoidance Education (SRAE) Program (New Collection), 16948-16949 [2020-06210]
Download as PDF
<![CDATA[
16948
Federal Register / Vol. 85, No. 58 / Wednesday, March 25, 2020 / Notices
ANNUAL BURDEN ESTIMATES
Instrument
Total
number of
respondents
Total
number of
responses per
respondent
Average
burden hours
per response
Total burden
hours
Annual
burden hours
Immediate Disaster Case Management Intake Assessment
1,564
1
1
1,564
521
Estimated Total Annual Burden
Hours: 521.
Comments: The Department
specifically requests comments on (a)
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Consideration will be given
to comments and suggestions submitted
within 60 days of this publication.
Administration for Children and
Families (ACF).
ACTION: Request for public comment.
Authority: Section 426 of the Robert T.
Stafford Disaster Relief and Emergency
Assistance Act, as amended, 42 U.S.C.
DATES:
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2020–06182 Filed 3–24–20; 8:45 am]
BILLING CODE 4184–PC–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Proposed Information Collection
Activity: Title V State Sexual Risk
Avoidance Education (SRAE) Program
(New Collection)
The Administration on
Children, Youth and Families (ACYF);
AGENCY:
The Administration on
Children, Youth and Families (ACYF),
Family and Youth Services Bureau
(FYSB) is accepting mandatory formula
grant applications and State Plans from
states and territories for the
development of and implementation for
Title V State Sexual Risk Avoidance
Education (SRAE) Program. The Title V
State SRAE Funding Opportunity
Announcement sets forth the
application requirements for the receipt
of the following documents from
applicants and awardees: Application,
State Plan, and Performance Progress
Report.
SUMMARY:
Comments due within 60 days of
publication. In compliance with the
requirements of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
ACF is soliciting public comment on the
specific aspects of the information
collection described above.
ADDRESSES: Copies of the proposed
collection of information can be
obtained and comments may be
forwarded by emailing infocollection@
acf.hhs.gov. Alternatively, copies can
also be obtained by writing to the
Administration for Children and
Families, Office of Planning, Research
and Evaluation (OPRE), 330 C Street
SW, Washington, DC 20201, Attn: ACF
Reports Clearance Officer. All requests,
emailed or written, should be identified
by the title of the information collection.
SUPPLEMENTARY INFORMATION:
Description: This Notice is to solicit
comments from the public on ACYF’s
proposed information collection
documents (application, State Plan, and
Performance Progress Report).
Purpose and Use of the Information
Collections: The application and State
Plan will offer information about the
proposed state project and it will be
used as the primary basis to determine
whether or not the project meets the
minimum requirements for the award.
The Performance Progress Report will
inform the monitoring of the grantees
program design, program evaluation,
management improvement, service
quality, and compliance with agreed
upon goals. ACYF/FYSB will use the
information to assure effective service
delivery. Finally, the data from this
collection will be used to report
outcomes and efficiencies and will
provide valuable information to policy
makers and key stakeholders in the
development of program and research
efforts.
Respondents: Fifty states and nine
territories, to include the District of
Columbia, Puerto Rico, Virgin Islands,
Guam, American Samoa, Northern
Mariana Islands, the Federated States of
Micronesia, the Marshall Islands, and
Palau.
ANNUAL BURDEN ESTIMATES
Total
number of
respondents
khammond on DSKJM1Z7X2PROD with NOTICES
Information collection title
Application ............................................................................
State Plan ............................................................................
Performance Progress Report .............................................
Estimated Annual Burden Total:
4,702.
Comments: The Department
specifically requests comments on (a)
VerDate Sep<11>2014
17:43 Mar 24, 2020
Jkt 250001
Total
number of
responses per
respondent
59
59
59
1
3
6
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
Average
burden hours
per response
24
40
16
Total
burden
hours
1,416
7,080
5,664
Annual
burden
hours
472
2,360
1,888
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
E:\FR\FM\25MRN1.SGM
25MRN1
Federal Register / Vol. 85, No. 58 / Wednesday, March 25, 2020 / Notices
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Consideration will be given
to comments and suggestions submitted
within 60 days of this publication.
(Authority: Section 510 (42 U.S.C. 710), as
amended by Section 50502 (Pub. L. 115–
123))
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2020–06210 Filed 3–24–20; 8:45 am]
BILLING CODE 4184–83–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket Nos. FDA–2020–D–1136, FDA–
2020–D–1137, FDA–2020–D–1138, FDA–
2020–D–1139, FDA–2020–D–1140, FDA–
2020–D–1141, FDA–2020–D–1142, and FDA–
2020–D–1143]
Process for Making Available
Guidance Documents Related to
Coronavirus Disease 2019
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing the process for making
available FDA guidance documents
related to the Coronavirus Disease 2019
(COVID–19) public health emergency.
FDA believes that this process will
allow the Agency to rapidly disseminate
essential Agency recommendations and
policies related to COVID–19 to
industry, FDA staff, and other
stakeholders.
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
FOR FURTHER INFORMATION CONTACT:
Kimberly Thomas, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6220,
Silver Spring, MD 20993–0002, 301–
796–2357; Stephen Ripley, Center for
Biologics Evaluation and Research,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm.
7268, Silver Spring, MD 20993–0002,
240–402–7911; Erica Takai, Center for
Devices and Radiological Health, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 5456,
Silver Spring, MD 20993–0002, 301–
796–6353; Phil Chao, Center for Food
Safety and Applied Nutrition, Food and
Drug Administration, CPK1 Rm. 1C001,
College Park, MD 20740, 240–402–2112;
VerDate Sep<11>2014
16:18 Mar 24, 2020
Jkt 250001
Diane Heinz, Center for Veterinary
Medicine, Food and Drug
Administration, 7500 Standish Pl.,
MPN2 RME435, HFV–6, Rockville, MD
20855, 240–402–5692; May Nelson,
Center for Tobacco Products, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 75, Rm. 4420,
Silver Spring, MD 20993–0002, 301–
796–9241; John Weiner, Office of the
Commissioner, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5130; Silver Spring,
MD 20993–0002, 301–796–8941; or Erik
Mettler, Office of Regulatory Affairs,
Food and Drug Administration, 12420
Parklawn Dr., ELEM Rm. 3008,
Rockville, MD 20857, 301–796–9254.
SUPPLEMENTARY INFORMATION:
I. Background
On January 31, 2020, as a result of
confirmed cases of COVID–19, and after
consultation with public health officials
as necessary, Alex M. Azar II, Secretary
of Health and Human Services, pursuant
to the authority under section 319 of the
Public Health Service Act (42 U.S.C.
247), determined that a public health
emergency exists and has existed since
January 27, 2020, nationwide.1 On
March 13, 2020, President Donald J.
Trump declared that the COVID–19
outbreak in the United States constitutes
a national emergency, beginning March
1, 2020.2 FDA is committed to providing
timely recommendations, regulatory
advice, guidance, and technical
assistance on an Agency-wide basis on
issues related to COVID–19, including
to clarify our expectations regarding
regulatory requirements to support
response efforts to this emergency. To
this end, FDA is announcing procedures
for making available FDA guidance
documents related to the COVID–19
public health emergency. FDA believes
that these procedures, which operate
within FDA’s established good guidance
practices regulations, will allow the
Agency to rapidly disseminate Agency
recommendations and policies related
to COVID–19 to industry, FDA staff, and
other stakeholders.
II. Procedures for Making COVID–19Related Guidance Documents Available
To facilitate issuance of guidance on
topics related to the COVID–19 public
1 Determination that a Public Health Emergency
Exists (January 31, 2020), available at https://
www.phe.gov/emergency/news/healthactions/phe/
Pages/2019-nCoV.aspx.
2 Proclamation on Declaring a National
Emergency Concerning the Novel Coronavirus
Disease (COVID–19) Outbreak (March 13, 2020),
available at https://www.whitehouse.gov/
presidential-actions/proclamation-declaringnational-emergency-concerning-novel-coronavirusdisease-covid-19-outbreak/.
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
16949
health emergency, the Agency intends
to use the following procedures:
• In light of the need to act quickly
and efficiently to respond to the
COVID–19 public health emergency,
FDA anticipates that prior public
participation will not be feasible or
appropriate before FDA implements
COVID–19-related guidance documents.
FDA anticipates it will issue COVID–19related guidance documents for
immediate implementation without
prior public comment (see section
701(h)(1)(C) of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C.
371(h)(1)(C)) and 21 CFR 10.115(g)(2)
(§ 10.115(g)(2)).
• Although FDA expects that COVID–
19-related guidances will be
implemented without prior comment,
FDA will solicit comment, review all
comments received, and revise the
guidance documents as appropriate (see
§ 10.115(g)(2)). Each guidance will
specify the docket number(s) to which
comments can be submitted.
• Guidance documents related to
COVID–19 will be accessible on the
internet from the FDA web page entitled
‘‘Coronavirus Disease 2019 (COVID–
19),’’ available at https://www.fda.gov/
emergency-preparedness-and-response/
mcm-issues/coronavirus-disease-2019covid-19.
• Guidance documents related to
COVID–19 may also be accessed from
the FDA web page entitled ‘‘Search for
FDA Guidance Documents’’ available at
https://www.fda.gov/regulatoryinformation/search-fda-guidancedocuments.
• Rather than publishing a separate
Notice of Availability (NOA) for each
COVID–19-related guidance document,
FDA intends to publish periodically a
consolidated NOA. This periodic NOA
will announce the availability of all the
COVID–19-related guidance documents
that issued during the relevant period.
The consolidated NOA will provide
instructions to the public on submitting
comments on COVID–19-related
guidance documents, including the
docket number(s) associated with each
guidance document, information on
how to view the dockets, and
instructions for persons interested in
obtaining a copy of a COVID–19-related
guidance document. In addition, the
guidance document will provide
information to the public on submitting
comments on the guidance document,
including the docket number(s)
associated with the guidance document
and instructions for persons interested
in obtaining a copy of a COVID–19related guidance document.
• FDA intends to establish one docket
for each Center or Office that may issue
E:\FR\FM\25MRN1.SGM
25MRN1
]]>Agencies
[Federal Register Volume 85, Number 58 (Wednesday, March 25, 2020)]
[Notices]
[Pages 16948-16949]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-06210]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Administration for Children and Families
Proposed Information Collection Activity: Title V State Sexual
Risk Avoidance Education (SRAE) Program (New Collection)
AGENCY: The Administration on Children, Youth and Families (ACYF);
Administration for Children and Families (ACF).
ACTION: Request for public comment.
-----------------------------------------------------------------------
SUMMARY: The Administration on Children, Youth and Families (ACYF),
Family and Youth Services Bureau (FYSB) is accepting mandatory formula
grant applications and State Plans from states and territories for the
development of and implementation for Title V State Sexual Risk
Avoidance Education (SRAE) Program. The Title V State SRAE Funding
Opportunity Announcement sets forth the application requirements for
the receipt of the following documents from applicants and awardees:
Application, State Plan, and Performance Progress Report.
DATES: Comments due within 60 days of publication. In compliance with
the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction
Act of 1995, ACF is soliciting public comment on the specific aspects
of the information collection described above.
ADDRESSES: Copies of the proposed collection of information can be
obtained and comments may be forwarded by emailing
[email protected]. Alternatively, copies can also be obtained
by writing to the Administration for Children and Families, Office of
Planning, Research and Evaluation (OPRE), 330 C Street SW, Washington,
DC 20201, Attn: ACF Reports Clearance Officer. All requests, emailed or
written, should be identified by the title of the information
collection.
SUPPLEMENTARY INFORMATION:
Description: This Notice is to solicit comments from the public on
ACYF's proposed information collection documents (application, State
Plan, and Performance Progress Report).
Purpose and Use of the Information Collections: The application and
State Plan will offer information about the proposed state project and
it will be used as the primary basis to determine whether or not the
project meets the minimum requirements for the award.
The Performance Progress Report will inform the monitoring of the
grantees program design, program evaluation, management improvement,
service quality, and compliance with agreed upon goals. ACYF/FYSB will
use the information to assure effective service delivery. Finally, the
data from this collection will be used to report outcomes and
efficiencies and will provide valuable information to policy makers and
key stakeholders in the development of program and research efforts.
Respondents: Fifty states and nine territories, to include the
District of Columbia, Puerto Rico, Virgin Islands, Guam, American
Samoa, Northern Mariana Islands, the Federated States of Micronesia,
the Marshall Islands, and Palau.
Annual Burden Estimates
----------------------------------------------------------------------------------------------------------------
Total number Average burden
Information collection title Total number of responses hours per Total burden Annual burden
of respondents per respondent response hours hours
----------------------------------------------------------------------------------------------------------------
Application..................... 59 1 24 1,416 472
State Plan...................... 59 3 40 7,080 2,360
Performance Progress Report..... 59 6 16 5,664 1,888
----------------------------------------------------------------------------------------------------------------
Estimated Annual Burden Total: 4,702.
Comments: The Department specifically requests comments on (a)
whether the proposed collection of information is necessary for the
proper performance of the functions of the agency, including whether
the information shall have practical utility; (b) the accuracy of the
agency's estimate of the burden of the proposed collection of
information; (c) the quality, utility,
[[Page 16949]]
and clarity of the information to be collected; and (d) ways to
minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Consideration will be given to
comments and suggestions submitted within 60 days of this publication.
(Authority: Section 510 (42 U.S.C. 710), as amended by Section 50502
(Pub. L. 115-123))
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2020-06210 Filed 3-24-20; 8:45 am]
BILLING CODE 4184-83-P
